Morgan Stanley provided color on Johnson & Johnson JNJ. In a research report published today, Morgan Stanley commented on the company's new product Xarelto.
In the report, Morgan Stanley states, "Positive apixaban data in the ARISTOTLE trial may
decrease commercial potential for J&J's Xarelto.
Bristol announced top line ARISTOLE results that
showed apixaban hit the superiority endpoint versus
warfarin in both efficacy and major bleeding. Using only
top line data to draw clear clinical conclusions can be
problematic, but it's fair to say today's announcement
presumptively shifts the debate in apixaban's favor."
At the moment, Morgan Stanley has an Overweight rating on the company's stock. On Wednesday, Johnson & Johnson lost 0.63% of its value to close the day at $66.07. Its shares continued to slide in today's pre-market trading, falling 0.56% to $65.70.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst Ratingsbristol myers squibbHealth CareJohnson & JohnsonMorgan StanleyPharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in